Product Information
ROSUVASTATIN CALCIUM 5 MG TAB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0321 per EA under NDC 57237016805. Its NADAC has been published 517 times since Nov 9, 2016.
FDA first approved this application on Jul 19, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
57237016805
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ROSUVASTATIN CALCIUMApproval Type
Generic (ANDA)
FDA Application
ANDA079170FDA Approved
7/19/2016
TE Code
AB
On Market Since
7/19/2016
Pharmacological Classes
Price Statistics
The NADAC for ROSUVASTATIN CALCIUM 5 MG TAB has been published 517 times since Nov 9, 2016, and over the history we have for it it has declined 91.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0321 per EA |
|---|---|
| All-time high | $0.3752 (Nov 16, 2016) |
| All-time low | $0.0321 (Sep 23, 2026) |
| 52-week high | $0.0385 |
| 52-week low | $0.0321 |
| Median price | $0.0675 |
| Average price | $0.0827 |
| Largest weekly change | -24.9% (Jan 18, 2017) |
| Weeks tracked | 517 |
| Tracking since | Nov 9, 2016 |
Generic Alternatives
The matcher finds 11 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Rosuvastatin Calcium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
HMG-CoA Reductase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ROSUVASTATIN CALCIUM 5 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for ROSUVASTATIN CALCIUM 5 MG TAB, manufactured by Rising Pharma Holdings Inc., is $0.0321 per EA (NDC 57237016805), effective Sep 30, 2026.
How has the price of ROSUVASTATIN CALCIUM 5 MG TAB changed over time?
Over the history we have for it, the NADAC for ROSUVASTATIN CALCIUM 5 MG TAB has declined 91.4%. It has been tracked across 517 weekly CMS publications since Nov 9, 2016.
What are the highest and lowest recorded NADAC prices for ROSUVASTATIN CALCIUM 5 MG TAB?
Since Nov 9, 2016, the NADAC for ROSUVASTATIN CALCIUM 5 MG TAB has ranged from a low of $0.0321 (Sep 23, 2026) to a high of $0.3752 (Nov 16, 2016), with a median of $0.0675 per EA.
Are there cheaper alternatives to ROSUVASTATIN CALCIUM 5 MG TAB?
11 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ROSUVASTATIN CALCIUM 5 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures ROSUVASTATIN CALCIUM 5 MG TAB?
ROSUVASTATIN CALCIUM 5 MG TAB (NDC 57237016805) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.